gene-delivery
(3)
Krish Krishnan Built the Biotech Before the Market Could Blink
An engineer learned finance, a scientist sketched an audacious idea, and a married pair funded the first experiment themselves. Ten years later, Krish Krishnan is still treating the IPO as the beginning, not the arrival.
Michael Chiu
Michael Chiu is the CEO of Kytopen, a Cambridge, Massachusetts biotech spun out of an MIT lab that builds the Flowfect platform - a non-viral, continuous-flow way to shuttle DNA, mRNA and CRISPR payloads into living cells at manufacturing scale. A mechanical engineer with a PhD and MBA from MIT, Chiu has spent his career turning laboratory hardware into shipped products, founding and selling companies in energy harvesting, healthcare, and bioprocessing before taking Kytopen's helm in August 2023 to push cell therapy manufacturing out of the bottleneck.
Kriya Therapeutics, Inc.
Kriya Therapeutics is a clinical-stage biopharmaceutical company building one-time, AAV-based gene therapies for prevalent chronic diseases of high unmet need. Founded in 2019 and headquartered in Morrisville, North Carolina with operations in Silicon Valley, Kriya pairs a proprietary, vertically integrated manufacturing and R&D engine with a pipeline spanning ophthalmology, metabolic disease, and neurology. Its bet: gene therapy shouldn't be reserved for the rare few, but engineered and manufactured at the scale and cost needed to reach millions.